Penumbra, Inc. (PEN)
USD 238.9
(-3.49%)
USD 238.9
(-3.49%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 90.95 Million USD | 4643.16% |
| 2022 | -2 Million USD | -176.32% |
| 2021 | 2.62 Million USD | 113.62% |
| 2020 | -19.25 Million USD | -139.74% |
| 2019 | 48.45 Million USD | 634.1% |
| 2018 | 6.6 Million USD | 41.74% |
| 2017 | 4.65 Million USD | -68.56% |
| 2016 | 14.81 Million USD | 526.38% |
| 2015 | 2.36 Million USD | 5.35% |
| 2014 | 2.24 Million USD | -45.23% |
| 2013 | 4.09 Million USD | 109.35% |
| 2012 | 1.95 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 11 Million USD | -79.71% |
| 2024 Q3 | 29.52 Million USD | 149.05% |
| 2024 Q2 | -60.2 Million USD | -647.17% |
| 2023 Q1 | 8.56 Million USD | 120.84% |
| 2023 Q2 | 18.96 Million USD | 121.44% |
| 2023 Q4 | 54.21 Million USD | 488.43% |
| 2023 Q3 | 9.21 Million USD | -51.4% |
| 2023 FY | 90.95 Million USD | 4643.16% |
| 2022 Q3 | -2.27 Million USD | 38.41% |
| 2022 Q4 | 3.87 Million USD | 270.72% |
| 2022 FY | -2 Million USD | -176.32% |
| 2022 Q1 | 79 Thousand USD | 100.32% |
| 2022 Q2 | -3.68 Million USD | -4767.09% |
| 2021 Q1 | 11.83 Million USD | 224.45% |
| 2021 Q2 | 9.23 Million USD | -22.01% |
| 2021 Q3 | 8.85 Million USD | -4.13% |
| 2021 FY | 2.62 Million USD | 113.62% |
| 2021 Q4 | -24.63 Million USD | -378.34% |
| 2020 Q2 | -11.96 Million USD | -939.3% |
| 2020 FY | -19.25 Million USD | -139.74% |
| 2020 Q4 | 3.64 Million USD | 141.38% |
| 2020 Q3 | -8.81 Million USD | 26.3% |
| 2020 Q1 | 1.42 Million USD | -85.29% |
| 2019 Q4 | 9.68 Million USD | -15.62% |
| 2019 Q3 | 11.48 Million USD | -30.78% |
| 2019 Q2 | 16.58 Million USD | 55.06% |
| 2019 Q1 | 10.69 Million USD | 60.65% |
| 2019 FY | 48.45 Million USD | 634.1% |
| 2018 Q4 | 6.65 Million USD | 135.18% |
| 2018 Q2 | 13.38 Million USD | 143.69% |
| 2018 Q1 | 5.49 Million USD | -39.55% |
| 2018 FY | 6.6 Million USD | 41.74% |
| 2018 Q3 | -18.93 Million USD | -241.47% |
| 2017 FY | 4.65 Million USD | -68.56% |
| 2017 Q4 | 9.08 Million USD | 3716.39% |
| 2017 Q3 | 238 Thousand USD | 115.28% |
| 2017 Q2 | -1.55 Million USD | 49.84% |
| 2017 Q1 | -3.1 Million USD | -29.63% |
| 2016 Q3 | -1.1 Million USD | -697.84% |
| 2016 Q1 | 780 Thousand USD | -52.24% |
| 2016 Q2 | 185 Thousand USD | -76.28% |
| 2016 Q4 | -2.39 Million USD | -116.64% |
| 2016 FY | 14.81 Million USD | 526.38% |
| 2015 Q1 | 2.5 Million USD | 501.44% |
| 2015 FY | 2.36 Million USD | 5.35% |
| 2015 Q4 | 1.63 Million USD | 81.24% |
| 2015 Q3 | 901 Thousand USD | 133.73% |
| 2015 Q2 | -2.67 Million USD | -206.75% |
| 2014 Q4 | 416 Thousand USD | 141.86% |
| 2014 Q2 | 75 Thousand USD | -73.21% |
| 2014 FY | 2.24 Million USD | -45.23% |
| 2014 Q3 | 172 Thousand USD | 129.33% |
| 2014 Q1 | 280 Thousand USD | 0.0% |
| 2013 FY | 4.09 Million USD | 109.35% |
| 2012 FY | 1.95 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Abbott Laboratories | 5.72 Billion USD | 98.411% |
| Allurion Technologies Inc. | -82.3 Million USD | 210.51% |
| Artivion, Inc. | -30.69 Million USD | 396.364% |
| Avanos Medical, Inc. | -61.8 Million USD | 247.175% |
| Butterfly Network, Inc. | -133.69 Million USD | 168.028% |
| Butterfly Network, Inc. | -133.69 Million USD | 168.028% |
| Bio-Rad Laboratories, Inc. | -637.32 Million USD | 114.271% |
| Boston Scientific Corporation | 1.59 Billion USD | 94.29% |
| Perspective Therapeutics, Inc. | -14.67 Million USD | 720.0% |
| CONMED Corporation | 64.45 Million USD | -41.104% |
| Edwards Lifesciences Corporation | 1.4 Billion USD | 93.514% |
| Paragon 28, Inc. | -47.84 Million USD | 290.117% |
| Glaukos Corporation | -134.66 Million USD | 167.543% |
| Globus Medical, Inc. | 122.87 Million USD | 25.977% |
| Inspire Medical Systems, Inc. | -21.15 Million USD | 529.982% |
| Integer Holdings Corporation | 90.65 Million USD | -0.335% |
| Medtronic plc | 3.67 Billion USD | 97.526% |
| Nevro Corp. | -92.21 Million USD | 198.635% |
| Owlet, Inc. | -32.9 Million USD | 376.448% |
| Vicarious Surgical Inc. | -71.07 Million USD | 227.976% |
| Smith & Nephew plc | 263 Million USD | 65.417% |
| Sonendo, Inc. | -60.91 Million USD | 249.303% |
| STERIS plc | 378.23 Million USD | 75.953% |
| Stryker Corporation | 3.16 Billion USD | 97.126% |
| Vapotherm, Inc. | -58.19 Million USD | 256.297% |
| Zimmer Biomet Holdings, Inc. | 1.02 Billion USD | 91.118% |